<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1497" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1497/" /><meta name="ncbi_pagename" content="MECP2 Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>MECP2 Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="MECP2 Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/09/19" /><meta name="citation_author" content="Simranpreet Kaur" /><meta name="citation_author" content="John Christodoulou" /><meta name="citation_pmid" content="20301670" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1497/" /><meta name="citation_keywords" content="MECP2 Classic Rett Syndrome" /><meta name="citation_keywords" content="MECP2-Related Severe Neonatal Encephalopathy" /><meta name="citation_keywords" content="Pyramidal Signs, Parkinsonism, and Macroorchidism (PPM-X) Syndrome" /><meta name="citation_keywords" content="Variant Rett Syndrome" /><meta name="citation_keywords" content="Methyl-CpG-binding protein 2" /><meta name="citation_keywords" content="MECP2" /><meta name="citation_keywords" content="MECP2 Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="MECP2 Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Simranpreet Kaur" /><meta name="DC.Contributor" content="John Christodoulou" /><meta name="DC.Date" content="2019/09/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1497/" /><meta name="description" content="The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability." /><meta name="og:title" content="MECP2 Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="The spectrum of MECP2-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical phenotype (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe syndromic/nonsyndromic intellectual disability." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1497/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/rett/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1497/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89BE00E0404DE1000000000996041A.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1497_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1497_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/thctd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mecp2-dup/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1497_"><span class="title" itemprop="name"><i>MECP2</i> Disorders</span></h1><p class="contrib-group"><span itemprop="author">Simranpreet Kaur</span>, MSc, M Phil and <span itemprop="author">John Christodoulou</span>, MBBS, PhD, FRACP, FFSc, FRCPA, FAHMS.</p><a data-jig="ncbitoggler" href="#__NBK1497_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1497_ai__"><div class="contrib half_rhythm"><span itemprop="author">Simranpreet Kaur</span>, MSc, M Phil<div class="affiliation small">Brain and Mitochondrial Research Group<br />Murdoch Children&#x02019;s Research Institute;<br />Department of Paediatrics<br />University of Melbourne<br />Parkville, Victoria, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.ude.ircm@ruak.narmis" class="oemail">ua.ude.ircm@ruak.narmis</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">John Christodoulou</span>, MBBS, PhD, FRACP, FFSc, FRCPA, FAHMS<div class="affiliation small">Professor, Pediatrics and Biochemical, Molecular, and Human Genetics<br />Theme Director, Genetics Research<br />Murdoch Children&#x02019;s Research Institute;<br />Chair of Genomic Medicine, Department of Pediatrics<br />University of Melbourne<br />Melbourne, Victoria, Australia<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ua.ude.ircm@uoluodotsirhc.nhoj" class="oemail">ua.ude.ircm@uoluodotsirhc.nhoj</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 3, 2001</span>; Last Update: <span itemprop="dateModified">September 19, 2019</span>.</p><p><em>Estimated reading time: 29 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="rett.Summary" itemprop="description"><h2 id="_rett_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>The spectrum of <i>MECP2</i>-related phenotypes in females ranges from classic Rett syndrome to variant Rett syndrome with a broader clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (either milder or more severe than classic Rett syndrome) to mild learning disabilities; the spectrum in males ranges from severe neonatal encephalopathy to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome to severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a>/nonsyndromic intellectual disability.</p><ul><li class="half_rhythm"><div><i>Females</i>: Classic Rett syndrome, a progressive neurodevelopmental disorder primarily affecting girls, is characterized by apparently normal psychomotor development during the first six to 18 months of life, followed by a short period of developmental stagnation, then rapid regression in language and motor skills, followed by long-term stability. During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use. Additional findings include fits of screaming and inconsolable crying, autistic features, panic-like attacks, bruxism, episodic apnea and/or hyperpnea, gait ataxia and apraxia, tremors, seizures, and acquired microcephaly.</div></li><li class="half_rhythm"><div><i>Males:</i> Severe neonatal-onset encephalopathy, the most common <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males, is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities. Death often occurs before age two years.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of a <i>MECP2</i> disorder is established by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> in a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with suggestive findings and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and in a male proband with suggestive findings and a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <i>MECP2</i> pathogenic variant.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment is mainly symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach that should also include psychosocial support for family members. Risperidone may help in treating agitation; melatonin can ameliorate sleep disturbances. Treatment of seizures, constipation, gastroesophageal reflux, scoliosis, prolonged QTc, and spasticity as per standard care.</p><p><i>Surveillance:</i> Periodic evaluation by the multidisciplinary team; regular assessment of QTc for evidence of prolongation; regular assessment for scoliosis.</p><p><i>Agents/circumstances to avoid:</i> Drugs known to prolong the QT interval.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>MECP2</i> disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner. More than 99% are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family), resulting from a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or possibly from inheritance of the pathogenic variant from a parent who has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Rarely, a <i>MECP2</i> variant may be inherited from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> mother in whom favorable skewing of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> results in minimal to no clinical findings. When the mother is a known <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>, the risk to her offspring of inheriting the <i>MECP2</i> variant is 50%. When the pathogenic <i>MECP2</i> variant has been identified in the family, heterozygote testing for at-risk female relatives, prenatal testing for pregnancies at increased risk, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible. Because of the possibility of parental germline mosaicism, it is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> to couples who have had a child with a <i>MECP2</i> disorder regardless of whether the <i>MECP2</i> pathogenic variant has been detected in a parent.</p></div></div><div id="rett.GeneReview_Scope"><h2 id="_rett_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="rett.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.Tc_1_1_1_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:top;"><i>MECP2</i> Disorders: Included Phenotypes&#x000a0;<sup>1,&#x000a0;2</sup></th></tr></thead><tbody><tr><td headers="hd_h_rett.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Females</b></td><td headers="hd_h_rett.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div><i>MECP2</i> classic Rett syndrome</div></li><li class="half_rhythm"><div>Variant Rett syndrome</div></li><li class="half_rhythm"><div>Mild learning disabilities</div></li></ul>
</td></tr><tr><td headers="hd_h_rett.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Males</b></td><td headers="hd_h_rett.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div><i>MECP2</i>-related severe neonatal encephalopathy</div></li><li class="half_rhythm"><div>Pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome</div></li><li class="half_rhythm"><div>Syndromic/nonsyndromic intellectual disability</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rett.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#rett.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd><dt>2. </dt><dd><div id="rett.TF.c.2"><p class="no_margin">Note: The allelic disorder <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> syndrome is not included in this <i>GeneReview</i>. See <a href="#rett.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</a>.</p></div></dd></dl></div></div></div></div><div id="rett.Diagnosis"><h2 id="_rett_Diagnosis_">Diagnosis</h2><p>Note: Duplication of <i>MECP2</i> (ranging from 0.3 to 4 Mb and larger) is associated with the allelic disorder <a href="/books/n/gene/mecp2-dup/"><i>MECP2</i> duplication syndrome</a> and is not addressed in this <i>GeneReview</i>.</p><div id="rett.Suggestive_Findings_in_Females"><h3>Suggestive Findings in Females</h3><p>A <i>MECP2</i> disorder <b>should be suspected/considered</b> in females with the following clinical findings suggestive of <i>MECP2</i> classic Rett syndrome or variant Rett syndrome (based on clinical diagnostic criteria published by <a class="bk_pop" href="#rett.REF.neul.2010.944">Neul et al [2010]</a> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058521/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>] prior to the widespread availability of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>), or mild learning disabilities.</p><p><b>Clinical findings of <i>MECP2</i></b>
<b>classic Rett syndrome and variant Rett syndrome</b></p><ul><li class="half_rhythm"><div>Most distinguishing finding: A period of regression (range: ages 1-4 years) followed by recovery or stabilization (range: ages 2-10 years; mean: age 5 years)</div></li><li class="half_rhythm"><div>Main findings</div><ul><li class="half_rhythm"><div>Partial or complete loss of acquired purposeful hand skills</div></li><li class="half_rhythm"><div>Partial or complete loss of acquired spoken language or language skill (e.g., babble)</div></li><li class="half_rhythm"><div>Gait abnormalities: impaired (dyspraxic) or absence of ability</div></li><li class="half_rhythm"><div>Stereotypic hand movements including hand wringing/squeezing, clapping/tapping, mouthing, and washing/rubbing automatisms</div></li></ul></li><li class="half_rhythm"><div>Supportive findings</div><ul><li class="half_rhythm"><div>Breathing disturbances when awake</div></li><li class="half_rhythm"><div>Bruxism when awake</div></li><li class="half_rhythm"><div>Impaired sleep pattern</div></li><li class="half_rhythm"><div>Abnormal muscle tone</div></li><li class="half_rhythm"><div>Peripheral vasomotor disturbances</div></li><li class="half_rhythm"><div>Scoliosis/kyphosis</div></li><li class="half_rhythm"><div>Growth retardation</div></li><li class="half_rhythm"><div>Small, cold hands and feet</div></li><li class="half_rhythm"><div>Inappropriate laughing/screaming spells</div></li><li class="half_rhythm"><div>Diminished response to pain</div></li><li class="half_rhythm"><div>Intense eye communication - "eye pointing"</div></li></ul></li><li class="half_rhythm"><div>Exclusionary findings</div><ul><li class="half_rhythm"><div>Brain injury secondary to peri- or postnatal trauma, neurometabolic disease, or severe infection that causes neurologic problems</div></li><li class="half_rhythm"><div>Grossly abnormal psychomotor development in the first six months of life, with early milestones not being met</div></li></ul></li></ul><p><b>Clinical findings of <i>MECP2</i> mild learning disability.</b> Typically mild and non-progressive. Note: Typically, females with mild learning disability are identified through <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> following diagnosis of a <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> (e.g., a more significantly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> brother or sister).</p></div><div id="rett.Suggestive_Findings_in_Males"><h3>Suggestive Findings in Males</h3><p><i>MECP2</i> disorders should be considered in a male with severe neonatal encephalopathy; pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome; or <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a>/nonsyndromic intellectual disability.</p><p><b>Clinical findings of <i>MECP2</i> severe neonatal encephalopathy</b></p><ul><li class="half_rhythm"><div>Microcephaly</div></li><li class="half_rhythm"><div>Relentless clinical course that follows a metabolic-degenerative type of pattern</div></li><li class="half_rhythm"><div>Abnormal tone</div></li><li class="half_rhythm"><div>Involuntary movements</div></li><li class="half_rhythm"><div>Severe seizures</div></li><li class="half_rhythm"><div>Breathing abnormalities (including central hypoventilation or respiratory insufficiency)</div></li></ul><p><b>Clinical findings of <i>MECP2</i> severe intellectual disability (including PPM-X syndrome)</b></p><ul><li class="half_rhythm"><div>Moderate-to-severe intellectual disability</div></li><li class="half_rhythm"><div>Resting tremor</div></li><li class="half_rhythm"><div>Slowness of movements</div></li><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>PPM-X syndrome: <i>p</i>yramidal signs, <i>p</i>arkinsonism, and <i>m</i>acroorchidism</div></li><li class="half_rhythm"><div>No seizures or microcephaly</div></li><li class="half_rhythm"><div>Usually normal brain MRI, EEG, EMG, and nerve conduction velocity studies</div></li></ul></div><div id="rett.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p><b>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of a <i>MECP2</i> disorder <b>is usually established</b> in a female proband with <a href="#rett.Suggestive_Findings_in_Females">suggestive findings</a> and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MECP2</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1497/table/rett.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figrettTmoleculargenetictestingusedin" rid-ob="figobrettTmoleculargenetictestingusedin">Table 1</a>).</p><p><b>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The diagnosis of a <i>MECP2</i> disorder <b>is established</b> in a male proband with <a href="#rett.Suggestive_Findings_in_Males">suggestive findings</a> and a <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MECP2</i> identified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1497/table/rett.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figrettTmoleculargenetictestingusedin" rid-ob="figobrettTmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (either single-gene or <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) or <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of <i>MECP2</i> disorders is broad, females with the distinctive findings described in <a href="#rett.Suggestive_Findings_in_Females">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#rett.Option_1">Option 1</a>), whereas females and males with a phenotype indistinguishable from many other inherited disorders with intellectual disability and/or neonatal encephalopathy are more likely to be diagnosed using genomic testing (see <a href="#rett.Option_2">Option 2</a>).</p><div id="rett.Option_1"><h4>Option 1</h4><p>When the clinical findings suggest the diagnosis of a <i>MECP2</i> disorder, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include use of single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing or a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>MECP2</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications. Note: Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletion on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted deletion/duplication analysis.</div></li><li class="half_rhythm"><div class="half_rhythm">Various <b>multigene panels</b> such as Rett/Angelman syndrome panels and more comprehensive childhood-onset epilepsy panels that include <i>MECP2</i> and other genes of interest (see <a href="#rett.Differential_Diagnosis">Differential Diagnosis</a>) are most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. For this disorder a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that also includes deletion/duplication analysis is recommended (see <a class="figpopup" href="/books/NBK1497/table/rett.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figrettTmoleculargenetictestingusedin" rid-ob="figobrettTmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="rett.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> overlaps with many other inherited disorders characterized by intellectual disability and/or neonatal encephalopathy, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is another option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="rett.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>MECP2</i> Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>MECP2</i></td><td headers="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3,&#x000a0;4</sup></td><td headers="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%-95%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_rett.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5%-10%&#x000a0;<sup>7,&#x000a0;8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rett.TF.1.1"><p class="no_margin">See <a href="/books/NBK1497/#rett.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="rett.TF.1.2"><p class="no_margin">See <a href="#rett.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="rett.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="rett.TF.1.4"><p class="no_margin">Lack of amplification by <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> prior to <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> can suggest a putative (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> on the X <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males; confirmation requires additional testing by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>.</p></div></dd><dt>5. </dt><dd><div id="rett.TF.1.5"><p class="no_margin"><a class="bk_pop" href="#rett.REF.archer.2006.451">Archer et al [2006]</a>, <a class="bk_pop" href="#rett.REF.philippe.2006.9">Philippe et al [2006]</a></p></div></dd><dt>6. </dt><dd><div id="rett.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by <a class="bk_pop" href="#rett.REF.hardwick.2007.1218">Hardwick et al [2007]</a>) may not be detected by these methods.</p></div></dd><dt>7. </dt><dd><div id="rett.TF.1.7"><p class="no_margin">The sizes of many reported disease-associated deletions are at the upper limits of detection by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and the lower limits of detection by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>; therefore, the proportion of pathogenic variants detected by either method depends on the methods used by a laboratory.</p></div></dd><dt>8. </dt><dd><div id="rett.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#rett.REF.archer.2006.451">Archer et al [2006]</a>, <a class="bk_pop" href="#rett.REF.pan.2006.418">Pan et al [2006]</a>, <a class="bk_pop" href="#rett.REF.philippe.2006.9">Philippe et al [2006]</a>, <a class="bk_pop" href="#rett.REF.hardwick.2007.1218">Hardwick et al [2007]</a>, <a class="bk_pop" href="#rett.REF.zahorakova.2007.342">Zahorakova et al [2007]</a></p></div></dd></dl></div></div></div></div></div></div><div id="rett.Clinical_Characteristics"><h2 id="_rett_Clinical_Characteristics_">Clinical Characteristics</h2><div id="rett.Clinical_Description"><h3>Clinical Description</h3><p>In females the spectrum of <i>MECP2</i>-related phenotypes ranges from classic Rett syndrome, to variant Rett syndrome (either milder or more severe than classic Rett syndrome), to mild learning disabilities. In males the spectrum ranges from severe neonatal encephalopathy, to pyramidal signs, parkinsonism, and macroorchidism (PPM-X) syndrome, to severe <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a>/nonsyndromic intellectual disability.</p><div id="rett.MECP2_Disorders_in_Females"><h4><i>MECP2</i> Disorders in Females</h4><div id="rett.T.features_of_mecp2_disorders_in_fe" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Features of MECP2 Disorders in Females</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.features_of_mecp2_disorders_in_fe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.features_of_mecp2_disorders_in_fe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Persons with Feature</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b><i>MECP2</i> classic Rett syndrome</b></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regression followed by recovery or stabilization</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deceleration of head growth</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gait abnormalities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">60%-80%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hand stereotypies &#x00026; loss of purposeful hand skills</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Absence of speech; high-pitched crying</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Cold extremities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Irregular breathing</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Variant Rett syndrome</b></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Regression followed by recovery or stabilization</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gait abnormalities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sleep disturbences</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%-80%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hand stereotypies &#x00026; loss of purposeful hand skills</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">97.3%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Breathing irregularities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-99%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Agitation</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_fe_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">80%-99%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#rett.REF.gold.2018.167">Gold et al [2018]</a>, <a class="bk_pop" href="#rett.REF.einspieler.2019.320">Einspieler &#x00026; Marschik [2019]</a>, <a class="bk_pop" href="#rett.REF.stallworth.2019.e2594">Stallworth et al [2019]</a></p></div></dd><dt>1. </dt><dd><div id="rett.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#rett.REF.stallworth.2019.e2594">Stallworth et al [2019]</a>; 44% showed different patterns including hand wringing, washing, clapping, and tapping.</p></div></dd></dl></div></div></div><p><b><i>MECP2</i> classic Rett syndrome.</b> Most individuals with classic Rett syndrome are female; however, males meeting the clinical criteria for classic Rett syndrome who have a 47,XXY <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a> [<a class="bk_pop" href="#rett.REF.hoffbuhr.2001.1486">Hoffbuhr et al 2001</a>, <a class="bk_pop" href="#rett.REF.leonard.2001.333">Leonard et al 2001</a>, <a class="bk_pop" href="#rett.REF.schwartzman.2001.162">Schwartzman et al 2001</a>] and postzygotic <i>MECP2</i> variants resulting in <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> have been described [<a class="bk_pop" href="#rett.REF.claytonsmith.2000.830">Clayton-Smith et al 2000</a>, <a class="bk_pop" href="#rett.REF.top_u.2002.77">Top&#x000e7;u et al 2002</a>].</p><p>Although early development is reportedly normal in children with classic Rett syndrome, parents &#x02013; in retrospect &#x02013; often identify subtle differences compared to unaffected sibs. Most (but not all) <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children have acquired microcephaly; stereotypic hand movements and breathing irregularities are seen in the majority.</p><p><b>Variant Rett syndrome.</b> Females with variant Rett syndrome exhibit a broader spectrum of clinical features than those observed in classic Rett syndrome. At the more severe end of the spectrum, development is delayed from very early infancy; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hypotonia and infantile spasms are also seen. At the milder end of the spectrum, regression is less dramatic and intellectual disability is much less severe; some speech may be preserved.</p><p><b>Mild learning disabilities.</b> In rare instances, females with a pathogenic <i>MECP2</i> variant may only exhibit mild learning disabilities or some autistic features, presumably as a consequence of favorable skewing of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. When there is no regression phase and no characteristic hand stereotypes, the clinical course differs from that of classic and variant Rett syndrome.</p></div><div id="rett.MECP2_Disorders_in_Males"><h4><i>MECP2</i> Disorders in Males</h4><div id="rett.T.features_of_mecp2_disorders_in_ma" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Features of <i>MECP2</i> Disorders in Males</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.features_of_mecp2_disorders_in_ma/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.features_of_mecp2_disorders_in_ma_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" style="text-align:left;vertical-align:middle;">Feature</th><th id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">%&#x000a0;of&#x000a0;Persons&#x000a0;with&#x000a0;Feature</th></tr><tr><th headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3" id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Present</th><th headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3" id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Absent</th><th headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3" id="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not<br />reported</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_1" rowspan="13" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>MECP2</i>-related<br />severe neonatal<br />encephalopathy&#x000a0;<sup>1</sup></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal birth parameters</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">71%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Head growth deceleration / microcephaly</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">94%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.8%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hypotonia &#x00026;/or feeding difficulties in infancy</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">82.4%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.6%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hypertonia of extremities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">52.9%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11.8%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.3%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Movement disorder, e.g., myoclonus, tremors, &#x00026; dystonia</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">58.8%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.5%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Mild cerebral atrophy</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Polymicrogyria</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.9%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.5%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70.6%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Poor head control</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">53%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">58.8%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.5%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Severe development delay</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">82.4%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17.6%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Irregular breathing / sleep apnea</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47.1%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">29.4%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23.5%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gastroesophageal reflux</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35.3%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">64.7%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">EEG abnormality</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">88.2%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.9%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.9%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_1" rowspan="16" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Pyramidal signs,<br />parkinsonism, and<br />macroorchidism<br />(PPM-X syndrome)&#x000a0;<sup>2</sup></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychosis</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">67.6%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.8%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">21.6%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Pyramidal signs</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">46%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">51.3%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Macroorchidism</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">19%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">81%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">97.3%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Progressive spasticity</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">67.6%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32.4%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Delayed development</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">54%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">46%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Speech difficulties</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Bilateral juvenile cataract</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Scoliosis or kyphosis</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10.8%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Large ears</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.1%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Movement disorders</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32.4%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Apraxia</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2.7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.1%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">91.9%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Dysmorphic features</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5.4%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">94.6%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_1" rowspan="12" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Syndromic/<br />nonsyndromic<br />intellectual<br />disability&#x000a0;<sup>3</sup></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe intellectual disability</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">90%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gait abnormalities</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">57%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">7%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Facial dysmorphism</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">87%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Behavioral problems</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">40%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">57%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Autistic-like behavior</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">53%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">44%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">30%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Poor/absent language skills</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">47%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">36%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hypotonia</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Microcephaly</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">23%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">64%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">History of regression</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">27%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">56%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Spasticity</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">33%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">17%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sleep disturbances</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">13%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td><td headers="hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_1_3 hd_h_rett.T.features_of_mecp2_disorders_in_ma_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">77%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rett.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#rett.REF.sch_le.2008.116">Sch&#x000fc;le et al [2008]</a></p></div></dd><dt>2. </dt><dd><div id="rett.TF.3.2"><p class="no_margin"><a class="bk_pop" href="#rett.REF.lindsay.1996.1120">Lindsay et al [1996]</a>, <a class="bk_pop" href="#rett.REF.claes.1997.155">Claes et al [1997]</a>, <a class="bk_pop" href="#rett.REF.gendrot.1999.411">Gendrot et al [1999]</a>, <a class="bk_pop" href="#rett.REF.orrico.2000.285">Orrico et al [2000]</a>, <a class="bk_pop" href="#rett.REF.klauck.2002.1034">Klauck et al [2002]</a>, <a class="bk_pop" href="#rett.REF.winnepenninckx.2002.249">Winnepenninckx et al [2002]</a>, <a class="bk_pop" href="#rett.REF.moog.2003.5">Moog et al [2003]</a>, <a class="bk_pop" href="#rett.REF.psoni.2010.551">Psoni et al [2010]</a></p></div></dd><dt>3. </dt><dd><div id="rett.TF.3.3"><p class="no_margin"><a class="bk_pop" href="#rett.REF.lubs.1999.243">Lubs et al [1999]</a>, <a class="bk_pop" href="#rett.REF.meloni.2000.982">Meloni et al [2000]</a>, <a class="bk_pop" href="#rett.REF.orrico.2000.285">Orrico et al [2000]</a>, <a class="bk_pop" href="#rett.REF.gomot.2003.129">Gomot et al [2003]</a>, <a class="bk_pop" href="#rett.REF.meins.2005.e12">Meins et al [2005]</a>, <a class="bk_pop" href="#rett.REF.van_esch.2005.442">Van Esch et al [2005]</a>, <a class="bk_pop" href="#rett.REF.ramocki.2009.771">Ramocki et al [2009]</a></p></div></dd></dl></div></div></div><p><b>Severe neonatal-onset encephalopathy</b> is characterized by a relentless clinical course that follows a metabolic-degenerative type of pattern, abnormal tone, involuntary movements, severe seizures, and breathing abnormalities (including central hypoventilation or respiratory insufficiency) [<a class="bk_pop" href="#rett.REF.wan.1999.1520">Wan et al 1999</a>, <a class="bk_pop" href="#rett.REF.villard.2000.1188">Villard et al 2000</a>, <a class="bk_pop" href="#rett.REF.zeev.2002.20">Zeev et al 2002</a>, <a class="bk_pop" href="#rett.REF.kankirawatana.2006.164">Kankirawatana et al 2006</a>]. Often, males with a severe neonatal encephalopathy die before age two years [<a class="bk_pop" href="#rett.REF.schanen.1998.229">Schanen et al 1998</a>, <a class="bk_pop" href="#rett.REF.wan.1999.1520">Wan et al 1999</a>].</p><p>The severe encephalopathy <a href="https://www.ncbi.nlm.nih.gov/books/n/gene/glossary/def-item/phenotype/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">phenotype</a> appears to be rare in females [<a class="bk_pop" href="#rett.REF.lugtenberg.2009.444">Lugtenberg et al 2009</a>].</p><p><b><a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> ID and PPM-X syndrome.</b> PPM-X syndrome, caused by the <a class="figpopup" href="/books/NBK1497/table/rett.T.notable_mecp2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figrettTnotablemecp2pathogenicvariants" rid-ob="figobrettTnotablemecp2pathogenicvariants">p.(Ala140Val)</a>
<i>MECP2</i> variant in males, is characterized by moderate-to-severe intellectual disability. Most have spasticity that may be progressive; some may have extrapyramidal movements. Episodic psychosis is seen in many but not all. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males also have macroorchidism. Microcephaly is variable. See also <a href="#rett.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div></div><div id="rett.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Genotype-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlations are inconsistent, due in part to the pattern of <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> (XCI); females who have a <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and favorably skewed XCI may have mild or no manifestations [<a class="bk_pop" href="#rett.REF.wan.1999.1520">Wan et al 1999</a>, <a class="bk_pop" href="#rett.REF.amir.2000.670">Amir et al 2000</a>, <a class="bk_pop" href="#rett.REF.cheadle.2000.1119">Cheadle et al 2000</a>, <a class="bk_pop" href="#rett.REF.huppke.2000.1369">Huppke et al 2000</a>, <a class="bk_pop" href="#rett.REF.weaving.2003.103">Weaving et al 2003</a>, <a class="bk_pop" href="#rett.REF.chae.2004.503">Chae et al 2004</a>, <a class="bk_pop" href="#rett.REF.schanen.2004.129">Schanen et al 2004</a>,<a class="bk_pop" href="#rett.REF.charman.2005.1121">Charman et al 2005</a>].</p><p><i>MECP2</i> pathogenic variants with some residual function that are associated with milder phenotypes include the following:</p><ul><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1497/table/rett.T.notable_mecp2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figrettTnotablemecp2pathogenicvariants" rid-ob="figobrettTnotablemecp2pathogenicvariants">p.(Ala140Val)</a>. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> (PPM-X) intellectual disability in males and very mild cognitive impairment in females [<a class="bk_pop" href="#rett.REF.dotti.2002.226">Dotti et al 2002</a>, <a class="bk_pop" href="#rett.REF.klauck.2002.1034">Klauck et al 2002</a>, <a class="bk_pop" href="#rett.REF.gomot.2003.129">Gomot et al 2003</a>, <a class="bk_pop" href="#rett.REF.venkateswaran.2014.91">Venkateswaran et al 2014</a>, <a class="bk_pop" href="#rett.REF.lambert.2016.522">Lambert et al 2016</a>, <a class="bk_pop" href="#rett.REF.sheikh.2016.38590">Sheikh et al 2016</a>].</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1497/table/rett.T.notable_mecp2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figrettTnotablemecp2pathogenicvariants" rid-ob="figobrettTnotablemecp2pathogenicvariants">p.(Arg133Cys)</a>. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is less severe than classic Rett syndrome in females; this variant can be present in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males [<a class="bk_pop" href="#rett.REF.leonard.2003.e52">Leonard et al 2003</a>, <a class="bk_pop" href="#rett.REF.sheikh.2016.38590">Sheikh et al 2016</a>].</div></li><li class="half_rhythm"><div><a class="figpopup" href="/books/NBK1497/table/rett.T.notable_mecp2_pathogenic_variants/?report=objectonly" target="object" rid-figpopup="figrettTnotablemecp2pathogenicvariants" rid-ob="figobrettTnotablemecp2pathogenicvariants">p.(Arg309Cys)</a> is found in females and males with intellectual disability and some features of <i>MECP2</i> disorders, but not classic or variant Rett syndrome [<a class="bk_pop" href="#rett.REF.campos.2007.293">Campos et al 2007</a>, <a class="bk_pop" href="#rett.REF.sch_newolfgreulich.2016.733">Sch&#x000f6;newolf-Greulich et al 2016</a>].</div></li></ul></div><div id="rett.Prevalence"><h3>Prevalence</h3><p>The worldwide prevalence is 1:10,000-1:23,000 female births [<a class="bk_pop" href="#rett.REF.ellaway.1999.162">Ellaway et al 1999</a>, <a class="bk_pop" href="#rett.REF.armstrong.2010">Armstrong et al 2010</a>]. Reports of incidence are limited; available estimates range from 0.43-0.71:10,000 for females in France [<a class="bk_pop" href="#rett.REF.bienvenu.2006.372">Bienvenu et al 2006</a>] to 0.586:10,000 for females in Serbia [<a class="bk_pop" href="#rett.REF.sarajlija.2015.1">Sarajlija et al 2015</a>] and 1.09:10,000 for females in Australia [<a class="bk_pop" href="#rett.REF.laurvick.2006.347">Laurvick et al 2006</a>].</p></div></div><div id="rett.Genetically_Related_Allelic_Disorde"><h2 id="_rett_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a href="/books/n/gene/mecp2-dup/"><b><i>MECP2</i> duplication syndrome</b></a> is characterized in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males by infantile hypotonia, delayed psychomotor development leading to severe intellectual disability, poor speech development, progressive spasticity, recurrent respiratory infections, and seizures.</p><p>Duplications of <i>MECP2</i> ranging from 0.3 to 4 Mb and larger are found in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males.</p><p>The birth prevalence of <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> syndrome has been reported to be 0.65:100,000 for all live births and 1:100,000 for males in Australia with the median age at diagnosis of 23.5 months [<a class="bk_pop" href="#rett.REF.giudicenairn.2019">Giudice-Nairn et al 2019</a>].</p></div><div id="rett.Differential_Diagnosis"><h2 id="_rett_Differential_Diagnosis_">Differential Diagnosis</h2><div id="rett.T.disorders_to_consider_in_the_diff" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of <i>MECP2</i> Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.disorders_to_consider_in_the_diff/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.disorders_to_consider_in_the_diff_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_1" style="text-align:left;vertical-align:middle;">Differential<br />Diagnosis<br />Disorder</th><th id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s) / Genetic Mechanism</th><th id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of Differential Diagnosis Disorder</th></tr><tr><th headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/<i>MECP2</i> Disorders</th><th headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4" id="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>MECP2</i> Disorders</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/angelman/">Angelman syndrome</a></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Deficient expression or function of maternally inherited <i>UBE3A</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 1</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ID, severe speech impairment, gait ataxia &#x00026;/or tremulousness of the limbs; microcephaly &#x00026; seizures common; DD 1st noted at age ~6 mos</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In classic Rett syndrome DD is not overtly evident in the 1st 6 mos.</td></tr><tr><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early infantile epileptic encephalopathy (OMIM <a href="https://omim.org/entry/300672" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300672</a>)</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CDKL5</i></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In females: early-onset severe seizures w/poor cognitive development; facial gestalt, cortical visual impairment;<br />In males: severe-profound ID &#x00026; early-onset intractable seizures&#x000a0;<sup>2</sup></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Very early-onset seizures, facial dysmorphism, &#x00026; cortical visual impairment are not generally seen in classic Rett syndrome.</td></tr><tr><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rett syndrome, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> variant (OMIM <a href="https://omim.org/entry/613454" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613454</a>)</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FOXG1</i></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short normal period of development before onset of regression leading to severe ID, DD, postnatal microcephaly, agenesis of the corpus callosum, seizures, dyskinesia, &#x00026; hypotonia&#x000a0;<sup>3</sup></td><td headers="hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_1_4 hd_h_rett.T.disorders_to_consider_in_the_diff_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Except for microcephaly, structural abnormalities are not usually seen on brain MRI.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; DD = developmental delay; ID = intellectual disability; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="rett.TF.4.1"><p class="no_margin">The risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic mechanism leading to the loss of <i>UBE3A</i> function: typically less than 1% risk for probands with a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> (UPD), and as high as 50% for probands with an <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a> defect or a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of <i>UBE3A</i>.</p></div></dd><dt>2. </dt><dd><div id="rett.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#rett.REF.elia.2008.997">Elia et al [2008]</a></p></div></dd><dt>3. </dt><dd><div id="rett.TF.4.3"><p class="no_margin">Overlapping features and a similar facial appearance between individuals with <i>FOXG1</i> pathogenic variants has led to the suggestion that these individuals should be regarded as having <i>FOXG1</i> syndrome rather than a variant of Rett syndrome [<a class="bk_pop" href="#rett.REF.kort_m.2011.396">Kort&#x000fc;m et al 2011</a>].</p></div></dd></dl></div></div></div></div><div id="rett.Management"><h2 id="_rett_Management_">Management</h2><div id="rett.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with a <i>MECP2</i> disorder, the evaluations summarized in <a class="figpopup" href="/books/NBK1497/table/rett.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="figrettTrecommendedevaluationsfollowing" rid-ob="figobrettTrecommendedevaluationsfollowing">Table 5</a> (if not performed as part of the evaluation that led to the diagnosis) are recommended.</p><div id="rett.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with a <i>MECP2</i> Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Constitutional</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of height, weight, &#x00026; head circumference</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl brain MRI; consider EEG / video monitoring if seizures are a concern.</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental assessment</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Motor, adaptive, cognitive, &#x00026; speech/language evaluation</div></li><li class="half_rhythm"><div>Evaluation for early intervention / special education</div></li></ul>
</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric/</b><br /><b>Behavioral</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychiatric evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In individuals age &#x0003e;12 mos: screening for behavior problems incl sleep disturbances, ADHD, anxiety, &#x00026;/or traits suggestive of ASD</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedics, physical medicine &#x00026; rehabilitation, PT, OT evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl assessment of:
<ul><li class="half_rhythm"><div>Gross motor &#x00026; fine motor skills</div></li><li class="half_rhythm"><div>Scoliosis</div></li><li class="half_rhythm"><div>Mobility &#x00026; activities of daily living &#x00026; need for adaptive devices</div></li><li class="half_rhythm"><div>Need for PT (to improve gross motor skills) &#x00026;/or OT (to improve fine motor skills)</div></li></ul>
</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal/</b><br /><b>Feeding</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gastroenterology / nutrition / feeding team evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl:
<ul><li class="half_rhythm"><div>Evaluation of aspiration risk &#x00026; nutritional status</div></li><li class="half_rhythm"><div>History of constipation &#x00026; GERD</div></li></ul>
Consider need for gastric tube placement.</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Overnight sleep studies</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Analysis for abnormalities of breathing regularity</div></li><li class="half_rhythm"><div>Noninvasive assessment of pulmonary gas exchange</div></li></ul>
</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sleep disorder</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Breathing monitoring using portable polygraphic screening devices</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess occurrence of apnea &#x00026; hypopnea</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for prolonged QTc</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Osteopenia</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bone densitometry</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for osteopenia</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for reduced vision, abnormal ocular movement, strabismus</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hearing</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Audiology evaluation</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess for hearing loss</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>ENT/Mouth</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Genitourinary</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Integument</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">History &#x00026; examination</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reduced perfusion of hands &#x00026; feet (possible autonomic abnormalities)</td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To incl <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a></td></tr><tr><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Family supports/resources</td><td headers="hd_h_rett.T.recommended_evaluations_following_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assess:
<ul><li class="half_rhythm"><div>Use of community or online resources, e.g., Parent to Parent</div></li><li class="half_rhythm"><div>Need for social work involvement for parental support</div></li><li class="half_rhythm"><div>Need for home nursing referral</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; GERD=gastroesophageal reflux disease; OT = occupational therapy; PT = physical therapy</p></div></dd></dl></div></div></div></div><div id="rett.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment needs to be individualized following an assessment of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's clinical problems and needs.</p><p>Management is symptomatic and focuses on optimizing the individual's abilities using a multidisciplinary approach with input from a pediatric or adult specialist physician, dietician, occupational therapist, speech therapist, music therapist, dentist, and other medical subspecialists as needed.</p><div id="rett.T.treatment_of_manifestations_in_in" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with a <i>MECP2</i> Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.treatment_of_manifestations_in_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.treatment_of_manifestations_in_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>DD/ID</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#rett.Developmental_Disability__Intellect">Developmental Delay / Intellectual Disability Management Issues</a>.</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Epilepsy</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standardized treatment w/AEDs by an experienced neurologist</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Many AEDs may be effective; no one AED has been demonstrated effective specifically for this disorder.</div></li><li class="half_rhythm"><div>Education of parents/caregivers&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric/</b><br /><b>Behavioral</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Risperidone (low dose) or selective serotonin uptake inhibitors have been somewhat successful in treating agitation.</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Scoliosis</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As per guidelines&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Poor weight</b><br /><b>gain / failure</b><br /><b>to thrive</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feeding therapy; gastrostomy tube placement may be required for persistent feeding issues</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low threshold for clinical feeding evaluation &#x00026;/or radiographic swallowing study when showing clinical signs or symptoms of dysphagia; nutritional guidelines are available.&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Spasticity</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Orthopedics / physical medicine &#x00026; rehabilitation / PT / OT incl stretching to help avoid contractures &#x00026; falls</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider need for positioning &#x00026; mobility devices, disability parking placard.</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Sleep disorder</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Melatonin can ameliorate sleep disturbances.</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chloral hydrate, hydroxyzine, or diphenhydramine may be used w/melatonin.</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Abnormal vision &#x00026;/or strabismus</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment(s) as recommended by ophthalmologist</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Community vision services through early intervention or school district</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Central visual impairment</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No specific treatment; early intervention to help stimulate visual development</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hearing</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing aids may be helpful as per otolaryngologist</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Community hearing services through early intervention or school district</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Constipation: stool softeners, prokinetics, osmotic agents, or laxatives as needed</div></li><li class="half_rhythm"><div>GERD: anti-reflux agents, smaller &#x00026; thickened feedings, &#x00026; positioning</div></li></ul>
</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment for prolonged QTc</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Under care of pediatric cardiologist</td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Osteopenia</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline densitometry; optimization of physical activity &#x00026; calcium &#x00026; vitamin D levels</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Guidelines for management of bone health are available.&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Family/</b><br /><b>Community</b></td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ensure appropriate social work involvement to connect families w/local resources, respite, &#x00026; support</div></li><li class="half_rhythm"><div>Care coordination to manage multiple subspecialty appointments, equipment, medications, &#x00026; supplies</div></li></ul>
</td><td headers="hd_h_rett.T.treatment_of_manifestations_in_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Ongoing assessment for need of palliative care involvement &#x00026;/or home nursing</div></li><li class="half_rhythm"><div>Consider involvement in adaptive sports or Special Olympics.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AED = antiepileptic drug; DD = developmental delay; GERD = gastroesophageal reflux disease; ID = intellectual disability</p></div></dd><dt>1. </dt><dd><div id="rett.TF.6.1"><p class="no_margin">Education of parents/caregivers regarding common seizure presentations is appropriate. For information on non-medical interventions and coping strategies for children diagnosed with epilepsy, see <a href="http://www.epilepsy.com/sites/core/files/atoms/files/English_Toolkit_updated%202014.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Epilepsy &#x00026; My Child Toolkit</a>.</p></div></dd><dt>2. </dt><dd><div id="rett.TF.6.2"><p class="no_margin"><a class="bk_pop" href="#rett.REF.downs.2009.e607">Downs et al [2009]</a></p></div></dd><dt>3. </dt><dd><div id="rett.TF.6.3"><p class="no_margin"><a class="bk_pop" href="#rett.REF.leonard.2013.451">Leonard et al [2013]</a></p></div></dd><dt>4. </dt><dd><div id="rett.TF.6.4"><p class="no_margin"><a class="bk_pop" href="#rett.REF.jefferson.2016.e0146824">Jefferson et al [2016]</a></p></div></dd></dl></div></div></div><div id="rett.Developmental_Disability__Intellect"><h4>Developmental Disability / Intellectual Disability Management Issues</h4><p>The following information represents typical management recommendations for individuals with developmental delay / intellectual disability in the United States; standard recommendations may vary from country to country.</p><p><b>Ages 0-3 years.</b> Referral to an early intervention program is recommended for access to occupational, physical, speech, and feeding therapy as well as infant mental health services, special educators, and sensory impairment specialists. In the US, early intervention is a federally funded program available in all states that provides in-home services to target individual therapy needs.</p><p><b>Ages 3-5 years.</b> In the US, developmental preschool through the local public school district is recommended. Before placement, an evaluation is made to determine needed services and therapies and an individualized education plan (IEP) is developed for those who qualify based on established motor, language, social, or cognitive delay. The early intervention program typically assists with this transition. Developmental preschool is center based; for children too medically unstable to attend, home-based services are provided.</p><p><b>All ages.</b> Consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate community, state, and educational agencies and to support parents in maximizing quality of life. Some issues to consider:</p><ul><li class="half_rhythm"><div>Individualized education plan (IEP) services:</div><ul><li class="half_rhythm"><div>An IEP provides specially designed instruction and related services to children who qualify.</div></li><li class="half_rhythm"><div>IEP services will be reviewed annually to determine if any changes are needed.</div></li><li class="half_rhythm"><div>As required by special education law, children should be in the least restrictive environment feasible at school and included in general education as much as possible and when appropriate.</div></li><li class="half_rhythm"><div>Vision and hearing consultants should be a part of the child's IEP team to support access to academic material.</div></li><li class="half_rhythm"><div>PT, OT, and speech services will be provided in the IEP to the extent that the need affects the child's access to academic material. Beyond that, private supportive therapies based on the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual's needs may be considered. Specific recommendations regarding type of therapy can be made by a developmental pediatrician.</div></li><li class="half_rhythm"><div>As a child enters teen years, a transition plan should be discussed and incorporated in the IEP. For those receiving IEP services, the public school district is required to provide services until age 21.</div></li></ul></li><li class="half_rhythm"><div>A 504 plan (Section 504: a US federal statute that prohibits discrimination based on disability) can be considered for those who require accommodations or modifications such as front-of-class seating, assistive technology devices, classroom scribes, extra time between classes, modified assignments, and enlarged text.</div></li><li class="half_rhythm"><div>Developmental Disabilities Administration (DDA) enrollment is recommended. DDA is a public agency that provides services and support to qualified individuals. Eligibility differs by state but is typically determined by diagnosis and/or associated cognitive/adaptive disabilities.</div></li><li class="half_rhythm"><div>Families with limited income and resources may also qualify for supplemental security income (SSI) for their child with a disability.</div></li></ul></div><div id="rett.Motor_Dysfunction"><h4>Motor Dysfunction</h4><p><b>Gross motor dysfunction</b></p><ul><li class="half_rhythm"><div>Physical therapy is recommended to maximize mobility and to reduce the risk for later-onset orthopedic complications (e.g., contractures, scoliosis, hip dislocation).</div></li><li class="half_rhythm"><div>Consider use of durable medical equipment and positioning devices as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, adaptive strollers).</div></li><li class="half_rhythm"><div>For muscle tone abnormalities including hypertonia or dystonia, consider involving appropriate specialists to aid in management of baclofen, tizanidine, Botox<sup>&#x000ae;</sup>, anti-parkinsonian medications, or orthopedic procedures.</div></li></ul><p><b>Fine motor dysfunction.</b> Occupational therapy is recommended for difficulty with fine motor skills that affect adaptive function such as feeding, grooming, dressing, and writing.</p><p><b>Oral motor dysfunction</b> should be assessed at each visit and clinical feeding evaluations and/or radiographic swallowing studies should be obtained for choking/gagging during feeds, poor weight gain, frequent respiratory illnesses, or feeding refusal that is not otherwise explained. Assuming that the child is safe to eat by mouth, feeding therapy (typically by an occupational or speech therapist) is recommended to improve coordination or sensory-related feeding issues. Feeds can be thickened or chilled for safety. When feeding dysfunction is severe, an NG-tube or G-tube may be necessary.</p><p><b>Communication issues.</b> Consider evaluation for alternative means of communication (e.g., <a href="http://www.asha.org/NJC/AAC/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Augmentative and Alternative Communication</a> [AAC]) for individuals who have expressive language difficulties. An AAC evaluation can be completed by a speech-language pathologist who has expertise in the area. The evaluation will consider cognitive abilities and sensory impairments to determine the most appropriate form of communication. AAC devices can range from low-tech, such as picture exchange communication, to high-tech, such as voice-generating devices. Contrary to popular belief, AAC devices do not hinder verbal development of speech and in many cases can improve it.</p></div><div id="rett.SocialBehavioral_Concerns"><h4>Social/Behavioral Concerns</h4><p>Children may qualify for and benefit from interventions used in treatment of autism spectrum disorder, including applied behavior analysis (ABA). ABA therapy is targeted to the individual child's behavioral, social, and adaptive strengths and weaknesses and typically performed one on one with a board-certified behavior analyst.</p><p>Consultation with a developmental pediatrician may be helpful in guiding parents through appropriate behavior management strategies or providing prescription medications, such as medication used to treat attention-deficit/hyperactivity disorder (ADHD), when necessary.</p><p>Concerns about serious aggressive or destructive behavior can be addressed by a pediatric psychiatrist.</p></div></div><div id="rett.Surveillance"><h3>Surveillance</h3><p>Many of the clinical features in females with atypical Rett syndrome (<a class="figpopup" href="/books/NBK1497/table/rett.T.features_of_mecp2_disorders_in_fe/?report=objectonly" target="object" rid-figpopup="figrettTfeaturesofmecp2disordersinfe" rid-ob="figobrettTfeaturesofmecp2disordersinfe">Table 2</a>) evolve with age and hence should be reassessed every six to 12 months.</p><div id="rett.T.recommended_surveillance_for_indi" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with a <i>MECP2</i> Disorder</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.recommended_surveillance_for_indi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.recommended_surveillance_for_indi_lrgtbl__"><table><thead><tr><th id="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Feeding</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of growth parameters</td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_3" rowspan="14" colspan="1" style="text-align:left;vertical-align:middle;">At each multidisciplinary<br />clinic visit;<br />minimum annually</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Evaluation of nutritional status &#x00026; safety of oral intake</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for constipation.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for evidence of aspiration, respiratory insufficiency.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor those w/seizures as clinically indicated.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Assess for new manifestations, e.g., seizures, changes in tone, movement disorders.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Development</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor developmental progress &#x00026; educational needs.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Speech &#x00026; language</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor communication skills.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Psychiatric/</b><br /><b>Behavioral</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Behavioral assessment for anxiety, attention, &#x00026; aggressive or self-injurious behavior</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical medicine, OT/PT assessment of mobility, self-help skills</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Monitor scoliosis.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitor for prolonged QTc.</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Respiratory</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Apnea/hyperventilation</td></tr><tr><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_rett.T.recommended_surveillance_for_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Assess family need for social work support (e.g., palliative/respite care, home nursing; other local resources) &#x00026; care coordination.</td></tr></tbody></table></div></div></div><div id="rett.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Because individuals with <i>MECP2</i> disorders are at increased risk for life-threatening arrhythmias associated with a prolonged QT interval, avoidance of drugs known to prolong the QT interval, including the following, is recommended:</p><ul><li class="half_rhythm"><div>Prokinetic agents (e.g., cisapride)</div></li><li class="half_rhythm"><div>Antipsychotics (e.g., thioridazine), tricyclic antidepressants (e.g., imipramine)</div></li><li class="half_rhythm"><div>Antiarrhythmics (e.g., quinidine, sotolol, amiodarone)</div></li><li class="half_rhythm"><div>Anesthetic agents (e.g., thiopental, succinylcholine)</div></li><li class="half_rhythm"><div>Antibiotics (e.g., erythromycin, ketoconazole)</div></li></ul><p>Click <a href="https://crediblemeds.org/pdftemp/pdf/DrugsToAvoidList.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">here</a> (pdf) for a more extensive list of drugs to avoid.</p></div><div id="rett.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#rett.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="rett.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>A number of clinical trials are currently under way, including observational studies, studies focused on improvement of language and communication skills, and drug trials.</p><p>For details see <a href="https://www.rettsyndrome.org/18-clinicaltrials" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rettsyndrome.org</a>.</p><p>Search <a href="http://clinicaltrials.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="rett.Genetic_Counseling"><h2 id="_rett_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="rett.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>MECP2</i> disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a> manner.</p></div><div id="rett.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Approximately 99.5% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in the family).</div></li><li class="half_rhythm"><div>Female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is recommended for both parents.</div></li><li class="half_rhythm"><div>Male <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>. <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is recommended for the mother. (Note: The father of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> male will not have a <i>MECP2</i> disorder nor will he be <a class="def" href="/books/n/gene/glossary/def-item/hemizygous/">hemizygous</a> for the <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, he does not require further evaluation/testing.)</div></li><li class="half_rhythm"><div>The mother of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who is found to be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>MECP2</i> variant may have favorably skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> that results in her being unaffected or mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>If the <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Maternal and paternal germline mosaicism have been reported [<a class="bk_pop" href="#rett.REF.amir.1999.185">Amir et al 1999</a>, <a class="bk_pop" href="#rett.REF.zeev.2002.20">Zeev et al 2002</a>, <a class="bk_pop" href="#rett.REF.mari.2005.258">Mari et al 2005</a>].</div><ul><li class="half_rhythm"><div>Maternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> was reported in one of nine pregnancies [<a class="bk_pop" href="#rett.REF.mari.2005.258">Mari et al 2005</a>, <a class="bk_pop" href="#rett.REF.ven_ncio.2007.902">Ven&#x000e2;ncio et al 2007</a>].</div></li><li class="half_rhythm"><div>Paternal <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> was reported in five fathers of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> daugthers from 21 families [<a class="bk_pop" href="#rett.REF.zhang.2019.1330">Zhang et al 2019</a>].</div></li></ul></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs depends on the genetic status of the parents:</p><ul><li class="half_rhythm"><div>If the mother of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has a <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the chance of transmitting it in each pregnancy is 50%.</div><ul><li class="half_rhythm"><div>Females who inherit the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at high risk of developing a <i>MECP2</i> disorder, although skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a> may result in a variable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>Males who inherit the variant may have a severe neonatal encephalopathy or, if they survive the first year, will most likely have a severe intellectual disability syndrome.</div></li></ul></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> represents a <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> case (i.e., a single occurrence in a family) and if the <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#rett.REF.amir.1999.185">Amir et al 1999</a>, <a class="bk_pop" href="#rett.REF.zeev.2002.20">Zeev et al 2002</a>, <a class="bk_pop" href="#rett.REF.mari.2005.258">Mari et al 2005</a>, <a class="bk_pop" href="#rett.REF.ven_ncio.2007.902">Ven&#x000e2;ncio et al 2007</a>, <a class="bk_pop" href="#rett.REF.zhang.2019.1330">Zhang et al 2019</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of a female <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a <i>MECP2</i> disorder has a 50% chance of inheriting the <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Females with more severe <i>MECP2</i> disorders do not reproduce; mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females have reproduced.</div></li><li class="half_rhythm"><div>Males with a <i>MECP2</i> disorder are not known to reproduce.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s mother: if the mother is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a pathogenic <i>MECP2</i> variant, her family members may be at risk.</p></div><div id="rett.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>First-degree female relatives.</b> Once the pathogenic <i>MECP2</i> variant has been identified in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, it is appropriate to offer testing to all first-degree female relatives regardless of their clinical status. Apparently unaffected sisters of a female proband with a <i>MECP2</i> disorder may be <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>MECP2</i> variant present in their sister but have few to no manifestations because of skewed <a class="def" href="/books/n/gene/glossary/def-item/x-chromosome-inactivation/">X-chromosome inactivation</a>. Genetic counseling should address this possibility as clinically unaffected sisters may be at risk of transmitting the pathogenic <i>MECP2</i> variant to their children.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or are at risk of having a pathogenic <i>MECP2</i> variant.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="rett.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible. Males with a <i>MECP2</i> variant who survive infancy will most likely have severe intellectual disability. The <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in a female with a <i>MECP2</i> variant is difficult to predict and can range from apparently normal to severely affected.</p><p>Note: Because parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for a <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been reported in multiple families, it is appropriate to offer prenatal testing to the parents of a child with a <i>MECP2</i> disorder whether or not the <i>MECP2</i> pathogenic variant has been identified in the leukocyte DNA of either parent.</p></div></div><div id="rett.Resources"><h2 id="_rett_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>International Rett Syndrome Foundation (IRSF)</b></div><div>4600 Devitt Drive</div><div>Cincinnati OH 45246</div><div><b>Phone:</b> 800-818-7388 (toll-free); 513-874-3020</div><div><b>Fax:</b> 513-874-2520</div><div><a href="http://www.rettsyndrome.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rettsyndrome.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Rett%20syndrome&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rett syndrome</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/rett-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rett syndrome</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22188/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rett syndrome</a></div></li><li class="half_rhythm"><div><b>Rett New Zealand</b></div><div>PO Box 28 049</div><div>Wellington </div><div>New Zealand</div><div><b>Phone:</b> 04 475 9265</div><div><b>Email:</b> rett.info@nzord.org.nz</div><div><a href="https://www.rettsyndrome.org.nz/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rettsyndrome.org.nz</a></div></li><li class="half_rhythm"><div><b>Rett Syndrome Europe</b></div><div><a href="https://www.rettsyndrome.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rettsyndrome.eu</a></div></li><li class="half_rhythm"><div><b>Rett Syndrome Research Trust</b></div><div>67 Under Cliff Road</div><div>Trumbull CT 06611</div><div><b>Phone:</b> 203-445-0041</div><div><b>Fax:</b> 203-445-9234</div><div><b>Email:</b> monica@rsrt.org</div><div><a href="http://www.rsrt.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rsrt.org</a></div></li><li class="half_rhythm"><div><b>Rett UK</b></div><div>Langham House West</div><div>Mill Street</div><div>Luton LU1 2NA</div><div>United Kingdom</div><div><b>Phone:</b> 01582 798 910</div><div><b>Email:</b> info@rettuk.org</div><div><a href="http://www.rettuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rettuk.org</a></div></li><li class="half_rhythm"><div><b>Australian Rett Syndrome Study / InterRett Registry</b></div><div>Telethon Institute for Child Health Research</div><div>PO Box 855</div><div>West Perth 6872</div><div>Australia</div><div><b>Phone:</b> +61 8 9489 7790; +61 419 956 946</div><div><b>Fax:</b> +61 8 9489 7700</div><div><b>Email:</b> rett@ichr.uwa.edu.au</div><div><a href="http://www.aussierett.org.au/about-us.aspx" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aussierett.org.au/about-us.aspx</a></div></li></ul></div><div id="rett.Molecular_Genetics"><h2 id="_rett_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="rett.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>MECP2 Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_rett.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_rett.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_rett.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_rett.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_rett.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_rett.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_rett.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4204" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MECP2</i></a></td><td headers="hd_b_rett.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4204" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Xq28</a></td><td headers="hd_b_rett.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51608" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Methyl-CpG-binding protein 2</a></td><td headers="hd_b_rett.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/MECP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MECP2 @ LOVD</a><br /><a href="https://research.cchmc.org/LOVD2/home.php?select_db=MECP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CCHMC - Human Genetics Mutation Database (MECP2)</a><br /><a href="http://mecp2.chw.edu.au/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RettBASE</a></td><td headers="hd_b_rett.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MECP2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MECP2</a></td><td headers="hd_b_rett.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MECP2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MECP2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="rett.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="rett.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for MECP2 Disorders (<a href="/omim/300005,300055,300496,300673,312750" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300005" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300005</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">METHYL-CpG-BINDING PROTEIN 2; MECP2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300055" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300055</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MENTAL RETARDATION, X-LINKED, SYNDROMIC 13; MRXS13</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300496" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300496</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">AUTISM, SUSCEPTIBILITY TO, X-LINKED 3; AUTSX3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/300673" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">300673</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ENCEPHALOPATHY, NEONATAL SEVERE, DUE TO MECP2 MUTATIONS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/312750" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">312750</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RETT SYNDROME; RTT</td></tr></tbody></table></div></div><div id="rett.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Loss of the protein MeCP2 leads to epigenetic aberrations of chromatin, suggesting that MeCP2 deficiency could lead to loss of <a class="def" href="/books/n/gene/glossary/def-item/imprinting/">imprinting</a>, thereby contributing to the pathogenesis of Rett syndrome [<a class="bk_pop" href="#rett.REF.horike.2005.31">Horike et al 2005</a>, <a class="bk_pop" href="#rett.REF.kaufmann.2005.331">Kaufmann et al 2005</a>, <a class="bk_pop" href="#rett.REF.makedonski.2005.1049">Makedonski et al 2005</a>].</p><p>The nuclear MeCP2 protein functional domains include:</p><ul><li class="half_rhythm"><div>Methyl binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (MBD): binds specifically to DNA at symmetrically methylated CpGs within chromatin [<a class="bk_pop" href="#rett.REF.hansen.2010.732">Hansen et al 2010</a>, <a class="bk_pop" href="#rett.REF.casasdelucchi.2012.e176">Casas-Delucchi et al 2012</a>]</div></li><li class="half_rhythm"><div>Transcription repression <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (TRD): responsible for recruiting other proteins that mediate transcription repression</div></li><li class="half_rhythm"><div>A-T hook <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>: basic residues that bind A-T rich DNA [<a class="bk_pop" href="#rett.REF.baker.2013.984">Baker et al 2013</a>, <a class="bk_pop" href="#rett.REF.heckman.2014.e02676">Heckman et al 2014</a>]</div></li><li class="half_rhythm"><div>WW <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>: conserved C-terminal domain [<a class="bk_pop" href="#rett.REF.buschdorf.2004.135">Buschdorf &#x00026; Stratling 2004</a>]</div></li></ul><p>It has also been shown that MeCP2 plays a role in <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> [<a class="bk_pop" href="#rett.REF.young.2005.17551">Young et al 2005</a>] and in long-range chromatin remodeling [<a class="bk_pop" href="#rett.REF.horike.2005.31">Horike et al 2005</a>], and may be a transcriptional activator [<a class="bk_pop" href="#rett.REF.chahrour.2008.1224">Chahrour et al 2008</a>].</p><p><b>Mechanism of disease causation.</b> Most pathogenic <i>MECP2</i> variants occur <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>. It has been suggested that pathogenic variants result in loss of protein function; some functional studies show that pathogenic <i>MECP2</i> variants affect the MBD or TRD domains of the abnormal protein, depending on the location of the variant [<a class="bk_pop" href="#rett.REF.kudo.2001.s165">Kudo et al 2001</a>, <a class="bk_pop" href="#rett.REF.kudo.2002.132">Kudo et al 2002</a>, <a class="bk_pop" href="#rett.REF.kudo.2003.487">Kudo et al 2003</a>].</p><p><b><i>MECP2</i>-specific laboratory technical considerations.</b> Two transcripts have been described:</p><ul><li class="half_rhythm"><div><a href="/nuccore/NM_001110792.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001110792.1</a>: encodes <i>MECP2_e1</i>, includes exons 1, 3, and 4 but not <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 (498 amino acids)</div></li><li class="half_rhythm"><div><a href="/nuccore/NM_004992.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004992.3</a>, encodes <i>MECP2_e2,</i> includes exons 2, 3, and 4 but not <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 (486 amino acids)</div></li></ul><p>Although the <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> are nearly identical, use of two alternative start codons creates alternative N-termini. The e1 transcript is much more highly expressed in brain than the e2 transcript [<a class="bk_pop" href="#rett.REF.kriaucionis.2004.1818">Kriaucionis &#x00026; Bird 2004</a>, <a class="bk_pop" href="#rett.REF.mnatzakanian.2004.339">Mnatzakanian et al 2004</a>].Of note:</p><ul><li class="half_rhythm"><div>Exon 1 (<i>MECP2_e1)</i>: pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1 are rare and include variants in the start codon (p.Met1?) and p.Ala2 as well as variant frameshift changes [<a class="bk_pop" href="#rett.REF.amir.2005.e15">Amir et al 2005</a>, <a class="bk_pop" href="#rett.REF.evans.2005.124">Evans et al 2005</a>, <a class="bk_pop" href="#rett.REF.poirier.2005.523">Poirier et al 2005</a>, <a class="bk_pop" href="#rett.REF.ravn.2005.324">Ravn et al 2005</a>, <a class="bk_pop" href="#rett.REF.saxena.2006.470">Saxena et al 2006</a>, <a class="bk_pop" href="#rett.REF.saunders.2009.1019">Saunders et al 2009</a>, <a class="bk_pop" href="#rett.REF.sheikh.2017.4132">Sheikh et al 2017</a>].</div></li><li class="half_rhythm"><div>Exon 2 (<i>MECP2_e2</i>): a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the start codon (p.Met1?) has been reported in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 [<a class="bk_pop" href="#rett.REF.gauthier.2005.321">Gauthier et al 2005</a>].</div></li></ul><p>The majority of pathogenic variants occur in the region encoding the methyl binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (MBD, exons 3 and 4; amino acids 90-174 of the MeCP2 e2 isoform), affecting the ability of the MeCP2 protein to bind to target DNA. A number of highly recurrent <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants are found in the transcriptional repression domain (TRD, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4; amino acids 219-322 of the MeCP2 e2 isoform) and beyond the TRD, a large number of frameshift variants delete the C-terminal end of the protein (3' end of exon 4).</p><div id="rett.T.notable_mecp2_pathogenic_variants" class="table"><h3><span class="label">Table 8. </span></h3><div class="caption"><p>Notable <i>MECP2</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1497/table/rett.T.notable_mecp2_pathogenic_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rett.T.notable_mecp2_pathogenic_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment [Reference]</th></tr></thead><tbody><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_1" rowspan="8" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_004492.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_004492<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_004983.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_004983<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.473C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Thr158Met)</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_4" rowspan="5" colspan="1" style="text-align:left;vertical-align:middle;">Common, recurrent pathogenic variants [<a class="bk_pop" href="#rett.REF.miltenbergermiltenyi.2003.107">Miltenberger-Miltenyi &#x00026; Laccone 2003</a>, <a class="bk_pop" href="#rett.REF.archer.2006.451">Archer et al 2006</a>, <a class="bk_pop" href="#rett.REF.philippe.2006.9">Philippe et al 2006</a>]</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.502C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg168Ter)</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.763C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg255Ter)</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.808C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg270Ter)</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.916C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg306Cys)</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.397C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg133Cys)</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in females is consistent w/in vitro functional studies showing that DNA binding is not impaired [<a class="bk_pop" href="#rett.REF.leonard.2003.e52">Leonard et al 2003</a>, <a class="bk_pop" href="#rett.REF.sheikh.2016.38590">Sheikh et al 2016</a>].</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.419C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Ala140Val)</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-classic, variant Rett syndrome, observed in <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases w/<a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> males [<a class="bk_pop" href="#rett.REF.dotti.2002.226">Dotti et al 2002</a>, <a class="bk_pop" href="#rett.REF.klauck.2002.1034">Klauck et al 2002</a>, <a class="bk_pop" href="#rett.REF.gomot.2003.129">Gomot et al 2003</a>, <a class="bk_pop" href="#rett.REF.venkateswaran.2014.91">Venkateswaran et al 2014</a>, <a class="bk_pop" href="#rett.REF.lambert.2016.522">Lambert et al 2016</a>, <a class="bk_pop" href="#rett.REF.sheikh.2016.38590">Sheikh et al 2016</a>]; <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> females may have mild ID &#x00026; impaired speech acquistion [<a class="bk_pop" href="#rett.REF.klauck.2002.1034">Klauck et al 2002</a>, <a class="bk_pop" href="#rett.REF.lambert.2016.522">Lambert et al 2016</a>].</td></tr><tr><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.925C&#x0003e;T</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(Arg309Trp)</td><td headers="hd_h_rett.T.notable_mecp2_pathogenic_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Observed in females &#x00026; males w/ID &#x00026; some features of a <i>MECP2</i> disorder, but not classic or variant Rett syndrome [<a class="bk_pop" href="#rett.REF.campos.2007.293">Campos et al 2007</a>, <a class="bk_pop" href="#rett.REF.sch_newolfgreulich.2016.733">Sch&#x000f6;newolf-Greulich et al 2016</a>]</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">ID = intellectual disability</p></div></dd><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div></div></div><div id="rett.References"><h2 id="_rett_References_">References</h2><div id="rett.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="rett.REF.downs.2009.e607">Downs J, Bergman A, Carter P, Anderson A, Palmer GM, Roye D, van Bosse H, Bebbington A, Larsson EL, Smith BG, Baikie G, Fyfe S, Leonard H. Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence. <span><span class="ref-journal">Spine. </span>2009;<span class="ref-vol">34</span>:E607–17.</span> [<a href="/pubmed/19644320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19644320</span></a>]</div></li></ul></div><div id="rett.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="rett.REF.amir.2005.e15">Amir RE, Fang P, Yu Z, Glaze DG, Percy AK, Zoghbi HY, Roa BB, Van den Veyver IB. Mutations in exon 1 of MECP2 are a rare cause of Rett syndrome. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:e15.</span> [<a href="/pmc/articles/PMC1735975/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735975</span></a>] [<a href="/pubmed/15689438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15689438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.amir.2000.670">Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, Philippi A, Timar L, Percy AK, Motil KJ, Lichtarge O, Smith EO, Glaze DG, Zoghbi HY. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. <span><span class="ref-journal">Ann Neurol. </span>2000;<span class="ref-vol">47</span>:670–9.</span> [<a href="/pubmed/10805343" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10805343</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.amir.1999.185">Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl- CpG-binding protein 2. <span><span class="ref-journal">Nat Genet. </span>1999;<span class="ref-vol">23</span>:185–8.</span> [<a href="/pubmed/10508514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10508514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.archer.2006.451">Archer HL, Whatley SD, Evans JC, Ravine D, Huppke P, Kerr A, Bunyan D, Kerr B, Sweeney E, Davies SJ, Reardon W, Horn J, MacDermot KD, Smith RA, Magee A, Donaldson A, Crow Y, Hermon G, Miedzybrodzka Z, Cooper DN, Lazarou L, Butler R, Sampson J, Pilz DT, Laccone F, Clarke AJ. Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:451–6.</span> [<a href="/pmc/articles/PMC2564520/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564520</span></a>] [<a href="/pubmed/16183801" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16183801</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.armstrong.2010">Armstrong AH, Hangauer J, Agazzi H, Nunez A, Gieron-Korthals M. Individuals with intellectual and developmental disabilities. In: David AS, ed. <em>Handbook of Pediatric Neuropsychology</em>. New York: Springer. 2010;537-50.</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.baker.2013.984">Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY. An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. <span><span class="ref-journal">Cell. </span>2013;<span class="ref-vol">152</span>:984–96.</span> [<a href="/pmc/articles/PMC3641682/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641682</span></a>] [<a href="/pubmed/23452848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23452848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.bienvenu.2006.372">Bienvenu T, Philippe C, de Roux N, Raynaud M, Bonnefond JP, Pasquier L, Lesca G, Mancini J, Jonveaux P, Moncla A, Feingold J, Chelly J, Villard L. The incidence of Rett syndrome in France. <span><span class="ref-journal">Pediatr Neurol. </span>2006;<span class="ref-vol">34</span>:372–5.</span> [<a href="/pubmed/16647997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16647997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.buschdorf.2004.135">Buschdorf JP, Stratling WH. A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome. <span><span class="ref-journal">J Mol Med. </span>2004;<span class="ref-vol">82</span>:135–43.</span> [<a href="/pubmed/14618241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14618241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.campos.2007.293">Campos M Jr, Abdalla CB, Santos-Rebou&#x000e7;as CB, dos Santos AV, Pestana CP, Domingues ML, dos Santos JM, Pimentel MM. Low significance of MECP2 mutations as a cause of mental retardation in Brazilian males. <span><span class="ref-journal">Brain Dev. </span>2007;<span class="ref-vol">29</span>:293–7.</span> [<a href="/pubmed/17084570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17084570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.casasdelucchi.2012.e176">Casas-Delucchi CS, Becker A, Bolius JJ, Cristina Cardoso M. Targeted manipulation of heterochromatin rescues MeCP2 Rett mutants and re-establishes higher order chromatin organization. <span><span class="ref-journal">Nucl Acids Res. </span>2012;<span class="ref-vol">40</span>:e176.</span> [<a href="/pmc/articles/PMC3526307/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3526307</span></a>] [<a href="/pubmed/22923521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22923521</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.chae.2004.503">Chae JH, Hwang H, Hwang YS, Cheong HJ, Kim KJ. Influence of MECP2 gene mutation and X-chromosome inactivation on the Rett syndrome phenotype. <span><span class="ref-journal">J Child Neurol. </span>2004;<span class="ref-vol">19</span>:503–8.</span> [<a href="/pubmed/15526954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15526954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.chahrour.2008.1224">Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY. MeCP2, a key contributor to neurological disease, activates and represses transcription. <span><span class="ref-journal">Science. </span>2008;<span class="ref-vol">320</span>:1224–9.</span> [<a href="/pmc/articles/PMC2443785/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2443785</span></a>] [<a href="/pubmed/18511691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18511691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.charman.2005.1121">Charman T, Neilson TC, Mash V, Archer H, Gardiner MT, Knudsen GP, McDonnell A, Perry J, Whatley SD, Bunyan DJ, Ravn K, Mount RH, Hastings RP, Hulten M, Orstavik KH, Reilly S, Cass H, Clarke A, Kerr AM, Bailey ME. Dimensional phenotypic analysis and functional categorisation of mutations reveal novel genotype-phenotype associations in Rett syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:1121–30.</span> [<a href="/pubmed/16077736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16077736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.cheadle.2000.1119">Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard H, Krawczak M, Cooper DN, Lynch S, Thomas N, Hughes H, Hulten M, Ravine D, Sampson JR, Clarke A. Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: correlation of disease severity with mutation type and location. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:1119–29.</span> [<a href="/pubmed/10767337" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10767337</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.claes.1997.155">Claes S, Devriendt K, D'Adamo P, Meireleire J, Raeymaekers P, Toniolo D, Cassiman JJ, Fryns JP. X-linked severe mental retardation and a progressive neurological disorder in a Belgian family: clinical and genetic studies. <span><span class="ref-journal">Clin Genet. </span>1997;<span class="ref-vol">52</span>:155–61.</span> [<a href="/pubmed/9377804" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9377804</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.claytonsmith.2000.830">Clayton-Smith J, Watson P, Ramsden S, Black GC. Somatic mutation in MECP2 as a non-fatal neurodevelopmental disorder in males. <span><span class="ref-journal">Lancet. </span>2000;<span class="ref-vol">356</span>:830–2.</span> [<a href="/pubmed/11022934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11022934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.dotti.2002.226">Dotti MT, Orrico A, De Stefano N, Battisti C, Sicurelli F, Severi S, Lam CW, Galli L, Sorrentino V, Federico A. A Rett syndrome MECP2 mutation that causes mental retardation in men. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">58</span>:226–30.</span> [<a href="/pubmed/11805248" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11805248</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.downs.2009.e607_1">Downs J, Bergman A, Carter P, Anderson A, Palmer GM, Roye D, van Bosse H, Bebbington A, Larsson EL, Smith BG, Baikie G, Fyfe S, Leonard H. Guidelines for management of scoliosis in Rett syndrome patients based on expert consensus and clinical evidence. <span><span class="ref-journal">Spine. </span>2009;<span class="ref-vol">34</span>:E607–17.</span> [<a href="/pubmed/19644320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19644320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.einspieler.2019.320">Einspieler C, Marschik PB. Regression in Rett syndrome: developmental pathways to its onset. <span><span class="ref-journal">Neurosci Biobehav Rev. </span>2019;<span class="ref-vol">98</span>:320–32.</span> [<a href="/pubmed/30832924" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30832924</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.elia.2008.997">Elia M, Falco M, Ferri R, Spalletta A, Bottitta M, Calabrese G, Carotenuto M, Musumeci SA, Lo Giudice M, Fichera M. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">71</span>:997–9.</span> [<a href="/pubmed/18809835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18809835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.ellaway.1999.162">Ellaway C, Williams K, Leonard H, Higgins G, Wilcken B, Christodoulou J. Rett syndrome: randomized controlled trial of L-carnitine. <span><span class="ref-journal">J Child Neurol. </span>1999;<span class="ref-vol">14</span>:162–7.</span> [<a href="/pubmed/10190267" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10190267</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.evans.2005.124">Evans JC, Archer HL, Whatley SD, Kerr A, Clarke A, Butler R. Variation in exon 1 coding region and promoter of MECP2 in Rett syndrome and controls. <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:124–6.</span> [<a href="/pubmed/15367913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15367913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.gauthier.2005.321">Gauthier J, de Amorim G, Mnatzakanian GN, Saunders C, Vincent JB, Toupin S, Kauffman D, St-Onge J, Laurent S, Macleod PM, Minassian BA, Rouleau GA. Clinical stringency greatly improves mutation detection in Rett syndrome. <span><span class="ref-journal">Can J Neurol Sci. </span>2005;<span class="ref-vol">32</span>:321–6.</span> [<a href="/pubmed/16225173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16225173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.gendrot.1999.411">Gendrot C, Ronce N, Raynaud M, Ayrault AD, Dourlens J, Castelnau P, Muh JP, Chelly J, Moraine C. X-linked nonspecific mental retardation (MRX16) mapping to distal Xq2 8: linkage study and neuropsychological data in a large family. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">83</span>:411–8.</span> [<a href="/pubmed/10232754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10232754</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.giudicenairn.2019">Giudice-Nairn P, Downs J, Wong K, Wilson D, Ta D, Gattas M, Amor D, Thompson E, Kirrali-Borri C, Ellaway C, Leonard H. The incidence, prevalence and clinical features of MECP2 duplication syndrome in Australian children. <span><span class="ref-journal">J Paediatr Child Health. </span>2019.</span> Epub ahead of print. [<a href="/pubmed/30756435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30756435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.gold.2018.167">Gold WA, Krishnaraj R, Ellaway C, Christodoulou J. Rett syndrome: a genetic update and clinical review focusing on comorbidities. <span><span class="ref-journal">ACS Chem Neurosci. </span>2018;<span class="ref-vol">9</span>:167–76.</span> [<a href="/pubmed/29185709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29185709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.gomot.2003.129">Gomot M, Gendrot C, Verloes A, Raynaud M, David A, Yntema HG, Dessay S, Kalscheuer V, Frints S, Couvert P, Briault S, Blesson S, Toutain A, Chelly J, Desportes V, Moraine C. MECP2 gene mutations in non-syndromic X-linked mental retardation: phenotype-genotype correlation. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">123A</span>:129–39.</span> [<a href="/pubmed/14598336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14598336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.hansen.2010.732">Hansen JC, Ghosh RP, Woodcock CL. Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin. <span><span class="ref-journal">IUBMB Life. </span>2010;<span class="ref-vol">62</span>:732–8.</span> [<a href="/pmc/articles/PMC3096928/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3096928</span></a>] [<a href="/pubmed/21031501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21031501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.hardwick.2007.1218">Hardwick SA, Reuter K, Williamson SL, Vasudevan V, Donald J, Slater K, Bennetts B, Bebbington A, Leonard H, Williams SR, Smith RL, Cloosterman D, Christodoulou J. Delineation of large deletions of the MECP2 gene in Rett syndrome patients, including a familial case with a male proband. <span><span class="ref-journal">Eur J Hum Genet. </span>2007;<span class="ref-vol">15</span>:1218–29.</span> [<a href="/pubmed/17712354" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17712354</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.heckman.2014.e02676">Heckman LD, Chahrour MH, Zoghbi HY. Rett-causing mutations reveal two domains critical for MeCP2 function and for toxicity in MECP2 duplication syndrome mice. <span><span class="ref-journal">eLife. </span>2014;<span class="ref-vol">3</span>:e02676.</span> [<a href="/pmc/articles/PMC4102243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4102243</span></a>] [<a href="/pubmed/24970834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24970834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.hoffbuhr.2001.1486">Hoffbuhr K, Devaney JM, LaFleur B, Sirianni N, Scacheri C, Giron J, Schuette J, Innis J, Marino M, Philippart M, Narayanan V, Umansky R, Kronn D, Hoffman EP, Naidu S. MeCP2 mutations in children with and without the phenotype of Rett syndrome. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">56</span>:1486–95.</span> [<a href="/pubmed/11402105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11402105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.horike.2005.31">Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. <span><span class="ref-journal">Nat Genet. </span>2005;<span class="ref-vol">37</span>:31–40.</span> [<a href="/pubmed/15608638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15608638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.huppke.2000.1369">Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F. Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. <span><span class="ref-journal">Hum Mol Genet. </span>2000;<span class="ref-vol">9</span>:1369–75.</span> [<a href="/pubmed/10814718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10814718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.jefferson.2016.e0146824">Jefferson A, Leonard H, Siafarikas A, Woodhead H, Fyfe S, Ward LM, Munns C, Motil K, Tarquinio D, Shapiro JR, Brismar T, Ben-Zeev B, Bisgaard AM, Coppola G, Ellaway C, Freilinger M, Geerts S, Humphreys P, Jones M, Lane J, Larsson G, Lotan M, Percy A, Pineda M, Skinner S, Syhler B, Thompson S, Weiss B, Witt Engerstr&#x000f6;m I, Downs J. Clinical guidelines for management of bone health in Rett syndrome based on expert consensus and available evidence. <span><span class="ref-journal">PLoS One. </span>2016;<span class="ref-vol">11</span>:e0146824.</span> [<a href="/pmc/articles/PMC4743907/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4743907</span></a>] [<a href="/pubmed/26849438" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26849438</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kankirawatana.2006.164">Kankirawatana P, Leonard H, Ellaway C, Scurlock J, Mansour A, Makris CM, Dure LS 4th, Friez M, Lane J, Kiraly-Borri C, Fabian V, Davis M, Jackson J, Christodoulou J, Kaufmann WE, Ravine D, Percy AK. Early progressive encephalopathy in boys and MECP2 mutations. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">67</span>:164–6.</span> [<a href="/pubmed/16832102" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16832102</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kaufmann.2005.331">Kaufmann WE, Jarrar MH, Wang JS, Lee YJ, Reddy S, Bibat G, Naidu S. Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation. <span><span class="ref-journal">Brain Dev. </span>2005;<span class="ref-vol">27</span>:331–9.</span> [<a href="/pubmed/16023547" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16023547</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.klauck.2002.1034">Klauck SM, Lindsay S, Beyer KS, Splitt M, Burn J, Poustka A. A mutation hot spot for nonspecific X-linked mental retardation in the MECP2 gene causes the PPM-X syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">70</span>:1034–7.</span> [<a href="/pmc/articles/PMC379098/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379098</span></a>] [<a href="/pubmed/11885030" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11885030</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kort_m.2011.396">Kort&#x000fc;m F, Das S, Flindt M, Morris-Rosendahl DJ, Stefanova I, Goldstein A, Horn D, Klopocki E, Kluger G, Martin P, Rauch A, Roumer A, Saitta S, Walsh LE, Wieczorek D, Uyanik G, Kutsche K, Dobyns WB. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:396–406.</span> [<a href="/pmc/articles/PMC5522617/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5522617</span></a>] [<a href="/pubmed/21441262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21441262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kriaucionis.2004.1818">Kriaucionis S, Bird A. The major form of MeCP2 has a novel N-terminus generated by alternative splicing. <span><span class="ref-journal">Nucleic Acids Res. </span>2004;<span class="ref-vol">32</span>:1818–23.</span> [<a href="/pmc/articles/PMC390342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC390342</span></a>] [<a href="/pubmed/15034150" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15034150</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kudo.2001.s165">Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Dragich J, Schanen C, Tamura M. Functional analyses of MeCP2 mutations associated with Rett syndrome using transient expression systems. <span><span class="ref-journal">Brain Dev. </span>2001;<span class="ref-vol">23</span>:S165–73.</span> [<a href="/pubmed/11738866" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11738866</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kudo.2002.132">Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Hammer S, Schanen C, Terai I, Tamura M. Functional characterisation of MeCP2 mutations found in male patients with X linked mental retardation. <span><span class="ref-journal">J Med Genet. </span>2002;<span class="ref-vol">39</span>:132–6.</span> [<a href="/pmc/articles/PMC1735040/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735040</span></a>] [<a href="/pubmed/11836365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11836365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.kudo.2003.487">Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Schanen C, Tamura M. Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:487–93.</span> [<a href="/pmc/articles/PMC1735522/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735522</span></a>] [<a href="/pubmed/12843318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12843318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.lambert.2016.522">Lambert S, Maystadt I, Boulanger S, Vrielynck P, Destr&#x000e9;e A, Lederer D, Moortgat S. Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation family with X-linked intellectual disability and spasticity. <span><span class="ref-journal">Eur J Med Genet. </span>2016;<span class="ref-vol">59</span>:522–5.</span> [<a href="/pubmed/27465203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27465203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.laurvick.2006.347">Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, Williamson S, Leonard H. Rett syndrome in Australia: a review of the epidemiology. <span><span class="ref-journal">J Pediatr. </span>2006;<span class="ref-vol">148</span>:347–52.</span> [<a href="/pubmed/16615965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16615965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.leonard.2003.e52">Leonard H, Colvin L, Christodoulou J, Schiavello T, Williamson S, Davis M, Ravine D, Fyfe S, de Klerk N, Matsuishi T, Kondo I, Clarke A, Hackwell S, Yamashita Y. Patients with the R133C mutation: is their phenotype different from patients with Rett syndrome with other mutations? <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:e52.</span> [<a href="/pmc/articles/PMC1735457/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735457</span></a>] [<a href="/pubmed/12746406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12746406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.leonard.2013.451">Leonard H, Ravikumara M, Baikie G, Naseem N, Ellaway C, Percy A, Abraham S, Geerts S, Lane J, Jones M, Bathgate K, Downs J, et al.  Assessment and management of nutrition and growth in Rett syndrome. <span><span class="ref-journal">J Pediatr Gastroenterol Nutr. </span>2013;<span class="ref-vol">57</span>:451–60.</span> [<a href="/pmc/articles/PMC3906202/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3906202</span></a>] [<a href="/pubmed/24084372" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24084372</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.leonard.2001.333">Leonard H, Silberstein J, Falk R, Houwink-Manville I, Ellaway C, Raffaele LS, Engerstrom IW, Schanen C. Occurrence of Rett syndrome in boys. <span><span class="ref-journal">J Child Neurol. </span>2001;<span class="ref-vol">16</span>:333–8.</span> [<a href="/pubmed/11392517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11392517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.lindsay.1996.1120">Lindsay S, Splitt M, Edney S, Berney TP, Knight SJ, Davies KE, O'Brien O, Gale M, Burn J. PPM-X: a new X-linked mental retardation syndrome with psychosis, pyramidal signs, and macroorchidism maps to Xq28. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">58</span>:1120–6.</span> [<a href="/pmc/articles/PMC1915053/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1915053</span></a>] [<a href="/pubmed/8651288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8651288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.lubs.1999.243">Lubs H, Abidi F, Bier JA, Abuelo D, Ouzts L, Voeller K, Fennell E, Stevenson RE, Schwartz CE, Arena F. XLMR syndrome characterized by multiple respiratory infections, hypertelorism, severe CNS deterioration and early death localizes to distal Xq28. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:243–8.</span> [<a href="/pubmed/10398236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10398236</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.lugtenberg.2009.444">Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, Raynaud M, Rating D, Journel H, Chelly J, Goizet C, Lacombe D, Pedespan JM, Echenne B, Tariverdian G, O'Rourke D, King MD, Green A, van Kogelenberg M, Van Esch H, Gecz J, Hamel BC, van Bokhoven H, de Brouwer AP. Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. <span><span class="ref-journal">Eur J Hum Genet. </span>2009;<span class="ref-vol">17</span>:444–53.</span> [<a href="/pmc/articles/PMC2986218/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2986218</span></a>] [<a href="/pubmed/18985075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18985075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.makedonski.2005.1049">Makedonski K, Abuhatzira L, Kaufman Y, Razin A, Shemer R. MeCP2 deficiency in Rett syndrome causes epigenetic aberrations at the PWS/AS imprinting center that affects UBE3A expression. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:1049–58.</span> [<a href="/pubmed/15757975" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15757975</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.mari.2005.258">Mari F, Caselli R, Russo S, Cogliati F, Ariani F, Longo I, Bruttini M, Meloni I, Pescucci C, Schurfeld K, Toti P, Tassini M, Larizza L, Hayek G, Zappella M, Renieri A. Germline mosaicism in Rett syndrome identified by prenatal diagnosis. <span><span class="ref-journal">Clin Genet. </span>2005;<span class="ref-vol">67</span>:258–60.</span> [<a href="/pubmed/15691364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15691364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.meins.2005.e12">Meins M, Lehmann J, Gerresheim F, Herchenbach J, Hagedorn M, Hameister K, Epplen JT. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:e12.</span> [<a href="/pmc/articles/PMC1735993/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735993</span></a>] [<a href="/pubmed/15689435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15689435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.meloni.2000.982">Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D'Adamo P, Denvriendt K, Fryns JP, Toniolo D, Renieri A. A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:982–5.</span> [<a href="/pmc/articles/PMC1287900/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1287900</span></a>] [<a href="/pubmed/10986043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10986043</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.miltenbergermiltenyi.2003.107">Miltenberger-Miltenyi G, Laccone F. Mutations and polymorphisms in the human methyl CpG-binding protein MECP2. <span><span class="ref-journal">Hum Mutat. </span>2003;<span class="ref-vol">22</span>:107–15.</span> [<a href="/pubmed/12872250" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12872250</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.mnatzakanian.2004.339">Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, MacLeod PJ, Jones JR, Scherer SW, Schanen NC, Friez MJ, Vincent JB, Minassian BA. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. <span><span class="ref-journal">Nat Genet. </span>2004;<span class="ref-vol">36</span>:339–41.</span> [<a href="/pubmed/15034579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15034579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.moog.2003.5">Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, Schoonbrood-Lenssen AM, Schrander-Stumpel CT. Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). <span><span class="ref-journal">Eur J Paediatr Neurol. </span>2003;<span class="ref-vol">7</span>:5–12.</span> [<a href="/pubmed/12615169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12615169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.neul.2010.944">Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, Leonard H, Bailey ME, Schanen NC, Zappella M, Renieri A, Huppke P, Percy AK, et al.  Rett syndrome: revised diagnostic criteria and nomenclature. <span><span class="ref-journal">Ann Neurol. </span>2010;<span class="ref-vol">68</span>:944–50.</span> [<a href="/pmc/articles/PMC3058521/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3058521</span></a>] [<a href="/pubmed/21154482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21154482</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.orrico.2000.285">Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, Poon PM, Zappella M, Federico A, Sorrentino V. MECP2 mutation in male patients with non-specific X-linked mental retardation. <span><span class="ref-journal">FEBS Lett. </span>2000;<span class="ref-vol">481</span>:285–8.</span> [<a href="/pubmed/11007980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11007980</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.pan.2006.418">Pan H, Li MR, Nelson P, Bao XH, Wu XR, Yu S. Large deletions of the MECP2 gene in Chinese patients with classical Rett syndrome. <span><span class="ref-journal">Clin Genet. </span>2006;<span class="ref-vol">70</span>:418–9.</span> [<a href="/pubmed/17026625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17026625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.philippe.2006.9">Philippe C, Villard L, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, Lesca G, Mancini J, Jonveaux P, Moncla A, Chelly J, Bienvenu T. Spectrum and distribution of MECP2 mutations in 424 Rett syndrome patients: a molecular update. <span><span class="ref-journal">Eur J Med Genet. </span>2006;<span class="ref-vol">49</span>:9–18.</span> [<a href="/pubmed/16473305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16473305</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.poirier.2005.523">Poirier K, Francis F, Hamel B, Moraine C, Fryns JP, Ropers HH, Chelly J, Bienvenu T. Mutations in exon 1 of MECP2B are not a common cause of X-linked mental retardation in males. <span><span class="ref-journal">Eur J Hum Genet. </span>2005;<span class="ref-vol">13</span>:523–4.</span> [<a href="/pubmed/15770224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15770224</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.psoni.2010.551">Psoni S, Sofocleous C, Traeger-Synodinos J, Kitsiou-Tzeli S, Kanavakis E, Fryssira-Kanioura H. Phenotypic and genotypic variability in four males with MECP2 gene sequence aberrations including a novel deletion. <span><span class="ref-journal">Pediatr Res. </span>2010;<span class="ref-vol">67</span>:551–6.</span> [<a href="/pubmed/20098342" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20098342</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.ramocki.2009.771">Ramocki MB, Peters SU, Tavyev YJ, Zhang F, Carvalho CM, Schaaf CP, Richman R, Fang P, Glaze DG, Lupski JR, Zoghbi HY. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. <span><span class="ref-journal">Ann Neurol. </span>2009;<span class="ref-vol">66</span>:771–82.</span> [<a href="/pmc/articles/PMC2801873/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2801873</span></a>] [<a href="/pubmed/20035514" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20035514</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.ravn.2005.324">Ravn K, Nielsen JB, Skjeldal OH, Kerr A, Hulten M, Schwartz M. Large genomic rearrangements in MECP2. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">25</span>:324.</span> [<a href="/pubmed/15712379" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15712379</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.sarajlija.2015.1">Sarajlija A, Kisic-Tepavcevic D, Nikolic Z, Savic Pavicevic D, Obradovic S, Djuric M, Pekmezovic T. Epidemiology of Rett syndrome in Serbia: prevalence, incidence and survival. <span><span class="ref-journal">Neuroepidemiology. </span>2015;<span class="ref-vol">44</span>:1–5.</span> [<a href="/pubmed/25571926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25571926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.saunders.2009.1019">Saunders CJ, Minassian BE, Chow EW, Zhao W, Vincent JB. Novel exon 1 mutations in MECP2 implicate isoform MeCP2_e1 in classical Rett syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1019–23.</span> [<a href="/pubmed/19365833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19365833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.saxena.2006.470">Saxena A, de Lagarde D, Leonard H, Williamson SL, Vasudevan V, Christodoulou J, Thompson E, MacLeod P, Ravine D. Lost in translation: translational interference from a recurrent mutation in exon 1 of MECP2. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:470–7.</span> [<a href="/pmc/articles/PMC2593027/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2593027</span></a>] [<a href="/pubmed/16155192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16155192</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.schanen.2004.129">Schanen C, Houwink EJ, Dorrani N, Lane J, Everett R, Feng A, Cantor RM, Percy A. Phenotypic manifestations of MECP2 mutations in classical and atypical Rett syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">126A</span>:129–40.</span> [<a href="/pubmed/15057977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15057977</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.schanen.1998.229">Schanen NC, Kurczynski TW, Brunelle D, Woodcock MM, Dure LS 4th, Percy AK. Neonatal encephalopathy in two boys in families with recurrent Rett syndrome. <span><span class="ref-journal">J Child Neurol. </span>1998;<span class="ref-vol">13</span>:229–31.</span> [<a href="/pubmed/9620015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9620015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.sch_newolfgreulich.2016.733">Sch&#x000f6;newolf-Greulich B, Tejada MI, Stephens K, Hadzsiev K, Gauthier J, Br&#x000f8;ndum-Nielsen K, Pfundt R, Ravn K, Maortua H, Gener B, Mart&#x000ed;nez-Bouzas C, Piton A, Rouleau G, Clayton-Smith J, Kleefstra T, Bisgaard AM, T&#x000fc;mer Z. The MECP2 variant c.925C&#x0003e;T (p.Arg309Trp) causes intellectual disability in both males and females without classic features of Rett syndrome. <span><span class="ref-journal">Clin Genet. </span>2016;<span class="ref-vol">89</span>:733–8.</span> [<a href="/pubmed/26936630" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26936630</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.sch_le.2008.116">Sch&#x000fc;le B, Armstrong DD, Vogel H, Oviedo A, Francke U. Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure. <span><span class="ref-journal">Clin Genet. </span>2008;<span class="ref-vol">74</span>:116–26.</span> [<a href="/pubmed/18477000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18477000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.schwartzman.2001.162">Schwartzman JS, Bernardino A, Nishimura A, Gomes RR, Zatz M. Rett syndrome in a boy with a 47,XXY karyotype confirmed by a rare mutation in the MECP2 gene. <span><span class="ref-journal">Neuropediatrics. </span>2001;<span class="ref-vol">32</span>:162–4.</span> [<a href="/pubmed/11521215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11521215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.sheikh.2016.38590">Sheikh TI, Ausi&#x000f3; J, Faghfoury H, Silver J, Lane JB, Eubanks JH, MacLeod P, Percy AK, Vincent JB. From function to phenotype: impaired DNA binding and clustering correlates with clinical severity in males with missense mutations in MECP2. <span><span class="ref-journal">Sci Rep. </span>2016;<span class="ref-vol">6</span>:38590.</span> [<a href="/pmc/articles/PMC5144150/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5144150</span></a>] [<a href="/pubmed/27929079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27929079</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.sheikh.2017.4132">Sheikh TI, de Paz AM, Akhtar S, Ausi&#x000f3; J, Vincent JB. MeCP2_E1 N-terminal modifications affect its degradation rate and are disrupted by the Ala2Val Rett mutation. <span><span class="ref-journal">Hum Mol Genet. </span>2017;<span class="ref-vol">26</span>:4132–41.</span> [<a href="/pmc/articles/PMC5886153/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5886153</span></a>] [<a href="/pubmed/28973632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28973632</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.stallworth.2019.e2594">Stallworth JL, Dy ME, Buchanan CB, Chen CF, Scott AE, Glaze DG, Lane JB, Lieberman DN, Oberman LM, Skinner SA, Tierney AE, Cutter GR, Percy AK, Neul JL, Kaufmann WE. Hand stereotypies: lessons from the Rett Syndrome Natural History Study. <span><span class="ref-journal">Neurology. </span>2019;<span class="ref-vol">92</span>:e2594–603.</span> [<a href="/pmc/articles/PMC6556084/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6556084</span></a>] [<a href="/pubmed/31053667" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31053667</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.top_u.2002.77">Top&#x000e7;u M, Akyerli C, Sayi A, Toruner GA, Kocoglu SR, Cimbis M, Ozcelik T. Somatic mosaicism for a MECP2 mutation associated with classic Rett syndrome in a boy. <span><span class="ref-journal">Eur J Hum Genet. </span>2002;<span class="ref-vol">10</span>:77–81.</span> [<a href="/pubmed/11896459" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11896459</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.van_esch.2005.442">Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, Hollanders K, Lugtenberg D, Bienvenu T, Jensen LR, Gecz J, Moraine C, Marynen P, Fryns JP, Froyen G. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. <span><span class="ref-journal">Am J Hum Genet. </span>2005;<span class="ref-vol">77</span>:442–53.</span> [<a href="/pmc/articles/PMC1226209/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226209</span></a>] [<a href="/pubmed/16080119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16080119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.ven_ncio.2007.902">Ven&#x000e2;ncio M, Santos M, Pereira SA, Maciel P, Saraiva JM. An explanation for another familial case of Rett syndrome: maternal germline mosaicism. <span><span class="ref-journal">Eur J Hum Genet. </span>2007;<span class="ref-vol">15</span>:902–4.</span> [<a href="/pubmed/17440498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17440498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.venkateswaran.2014.91">Venkateswaran S, McMillan HJ, Doja A, Humphreys P. Adolescent onset cognitive regression and neuropsychiatric symptoms associated with the A140V MECP2 mutation. <span><span class="ref-journal">Dev Med Child Neurol. </span>2014;<span class="ref-vol">56</span>:91–4.</span> [<a href="/pubmed/24328834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24328834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.villard.2000.1188">Villard L, Kpebe A, Cardoso C, Chelly PJ, Tardieu PM, Fontes M. Two affected boys in a Rett syndrome family: clinical and molecular findings. <span><span class="ref-journal">Neurology. </span>2000;<span class="ref-vol">55</span>:1188–93.</span> [<a href="/pubmed/11071498" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11071498</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.wan.1999.1520">Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial MECP2 mutations at CpG hotspots. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">65</span>:1520–9.</span> [<a href="/pmc/articles/PMC1288362/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1288362</span></a>] [<a href="/pubmed/10577905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10577905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.weaving.2003.103">Weaving LS, Williamson SL, Bennetts B, Davis M, Ellaway CJ, Leonard H, Thong MK, Delatycki M, Thompson EM, Laing N, Christodoulou J. Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">118A</span>:103–14.</span> [<a href="/pubmed/12655490" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12655490</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.winnepenninckx.2002.249">Winnepenninckx B, Errijgers V, Hayez-Delatte F, Reyniers E, Frank Kooy R. Identification of a family with nonspecific mental retardation (MRX79) with the A140V mutation in the MECP2 gene: is there a need for routine screening? <span><span class="ref-journal">Hum Mutat. </span>2002;<span class="ref-vol">20</span>:249–52.</span> [<a href="/pubmed/12325019" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12325019</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.young.2005.17551">Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, Kang D, Richman R, Johnson JM, Berget S, Zoghbi HY. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2005;<span class="ref-vol">102</span>:17551–8.</span> [<a href="/pmc/articles/PMC1266160/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1266160</span></a>] [<a href="/pubmed/16251272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16251272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.zahorakova.2007.342">Zahorakova D, Rosipal R, Hadac J, Zumrova A, Bzduch V, Misovicova N, Baxova A, Zeman J, Martasek P. Mutation analysis of the MECP2 gene in patients of Slavic origin with Rett syndrome: novel mutations and polymorphisms. <span><span class="ref-journal">J Hum Genet. </span>2007;<span class="ref-vol">52</span>:342–8.</span> [<a href="/pubmed/17387578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17387578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.zeev.2002.20">Zeev BB, Yaron Y, Schanen NC, Wolf H, Brandt N, Ginot N, Shomrat R, Orr-Urtreger A. Rett syndrome: clinical manifestations in males with MECP2 mutations. <span><span class="ref-journal">J Child Neurol. </span>2002;<span class="ref-vol">17</span>:20–4.</span> [<a href="/pubmed/11913564" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11913564</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rett.REF.zhang.2019.1330">Zhang Q, Yang X, Wang J, Li J, Wu Q, Wen Y, Zhao Y, Zhang X, Yao H, Wu X, Yu S, Wei L, Bao X. Genomic mosaicism in the pathogenesis and inheritance of a Rett syndrome cohort. <span><span class="ref-journal">Genet Med. </span>2019;<span class="ref-vol">21</span>:1330–8.</span> [<a href="/pmc/articles/PMC6752670/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6752670</span></a>] [<a href="/pubmed/30405208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30405208</span></a>]</div></li></ul></div></div><div id="rett.Chapter_Notes"><h2 id="_rett_Chapter_Notes_">Chapter Notes</h2><div id="rett.Author_History"><h3>Author History</h3><p>Vicky L Brandt; Baylor College of Medicine (2000-2004)<br />John Christodoulou, MBBS, PhD, FRACP, FRCPA, FHGSA (2006-present)<br />Gladys Ho, MSc; Children's Hospital at Westmead, Sydney (2009-2019)<br />Simranpreet Kaur, MSci, MPhil (2019-present)<br />Huda Y Zoghbi, MD; Baylor College of Medicine (2004-2006)</p></div><div id="rett.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 September 2019 (bp) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 June 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 April 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2008 (cd) Revision: <i>MECP2</i> <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> syndrome added to Genetically Related Disorders</div></li><li class="half_rhythm"><div>15 August 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 February 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 October 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>September 2000 (vb) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1497</span><span class="label">PMID: <a href="/pubmed/20301670" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301670</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/thctd/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/mecp2-dup/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1497&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1497/?report=reader">PubReader</a></li><li><a href="/books/NBK1497/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1497" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1497" style="display:none" title="Cite this Page"><div class="bk_tt">Kaur S, Christodoulou J. MECP2 Disorders. 2001 Oct 3 [Updated 2019 Sep 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1497/pdf/Bookshelf_NBK1497.pdf">PDF version of this page</a> (566K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#rett.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#rett.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#rett.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#rett.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#rett.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#rett.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#rett.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#rett.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#rett.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#rett.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#rett.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#rett.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4204[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MECP2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1497+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1478694" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1478694" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1478694" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1478694" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24278995" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CASK</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moog U, Uyanik G, Kutsche K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301294" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">ATP1A3-</i>Related Neurologic Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301487" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Smith-Magenis Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Smith-Magenis Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Smith ACM, Boyd KE, Brennan C, Charles J, Elsea SH, Finucane BM, Foster R, Gropman A, Girirajan S, Haas-Givler B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301670" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301670" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04183b75f66d18aa7fcd3e">MECP2 Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">MECP2 Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:17:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89BE00E0404DE1000000000996041A&amp;ncbi_session=CE89BE00E04183A1_2454SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1497%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1497&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1497/&amp;ncbi_pagename=MECP2 Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89BE00E04183A1_2454SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>